Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Assets Average (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Assets Average for 5 consecutive years, with $48.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets Average fell 44.45% to $48.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $48.1 million, a 44.45% decrease, with the full-year FY2024 number at $104.5 million, down 17.27% from a year prior.
  • Assets Average was $48.1 million for Q3 2025 at Lyra Therapeutics, down from $54.4 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $142.1 million in Q1 2024 to a low of $48.1 million in Q3 2025.
  • A 5-year average of $90.9 million and a median of $87.7 million in 2022 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: soared 99.42% in 2023, then plummeted 56.83% in 2025.
  • Lyra Therapeutics' Assets Average stood at $61.3 million in 2021, then soared by 87.09% to $114.7 million in 2022, then rose by 14.71% to $131.6 million in 2023, then tumbled by 44.86% to $72.6 million in 2024, then tumbled by 33.65% to $48.1 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Assets Average are $48.1 million (Q3 2025), $54.4 million (Q2 2025), and $61.3 million (Q1 2025).